Last Updated: August 9, 2026

Details for Patent: 12,310,935

Name: Drug Patent Intelligence for US Patent 12310935
Creator: DrugPatentWatch
License: https://www.drugpatentwatch.com/terms.php

✉ Email this page to a colleague

« Back to Dashboard

Which drugs does patent 12,310,935 protect, and when does it expire?

Patent 12,310,935 protects IQIRVO and is included in one NDA.

This patent has forty-six patent family members in thirty-one countries.

Summary for Patent: 12,310,935

Title:	Methods of treatment of cholestatic diseases
Abstract:	The present invention relates to the use of compound 1-[4-methylthiophenyl]-3-[3,5-dimethyl-4-carboxydimethylmethyloxyphenyl]prop-2-en-1-one (Elafibranor or GFT505) for treating cholestatic diseases, and more specifically PBC and/or PSC.
Inventor(s):	Remy HANF
Assignee:	Genfit SA
Application Number:	US18/505,898
Patent Claim Types: see list of patent claims	Use; Composition; Device; Dosage form;

Drugs Protected by US Patent 12,310,935

Glossary

Subscribe to access the full database, or Start Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Ipsen	IQIRVO	elafibranor	TABLET;ORAL	218860-001	Jun 10, 2024		RX	Yes	Yes	⤷ Start Trial	⤷ Start Trial				TREATMENT OF PRIMARY BILIARY CHOLANGITIS (PBC)	⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

International Family Members for US Patent 12,310,935

Subscribe to access the full database, or Start Trial
Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
European Patent Office	3435996	⤷ Start Trial	301342	Netherlands	⤷ Start Trial
European Patent Office	3435996	⤷ Start Trial	C20250032	Finland	⤷ Start Trial
European Patent Office	3435996	⤷ Start Trial	CA 2025 00035	Denmark	⤷ Start Trial
European Patent Office	3435996	⤷ Start Trial	PA2025535	Lithuania	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.